Endpoints News

Corvus' latest Ph1 data meet high expectations		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M Tue W Th F

20 January, 2026

sponsored by

#JPM26 Spotlights. Excellent Human-Monkey Cross-Reactivity. This CD3-VHH Potently Accelerates the Clinical Translation of TCE Drugs

Overcome the species gap in preclinical TCE development. Fapon Biopharma's CD3-VHH exhibits excellent human-monkey cross-reactivity, enabling reliable safety & efficacy studies in NHP models. Ideal for bispecific/trispecific TCEs, in vivo CAR-T, and TCR-T therapies. Ready to de-risk and accelerate your program?

Learn More

presented by

A Psychedelic Renaissance: How Definium Therapeutics is Changing How We Think about LSD and Treat Mental Health

news

GSK makes $2.2B deal for RAPT and its food allergy candidate

Corvus' new Phase 1 atopic dermatitis data meet high expectations

Pfizer to depart GSK's ViiV as Shionogi doubles its stake

Isomorphic signs another pharma deal, partnering with J&J for AI-made drugs

Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM

Exciva raises $59M to fund Phase 2 test of Alzheimer’s agitation drug

ENDPOINTS PHARMA

AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study

Makary cites higher FDA user fees as one key to counter China biotech

Large drugmakers without a US pricing pact are bracing to make one

Supreme Court will hear Hikma’s ‘skinny label’ fight against Amarin

in case you missed it

Generic GLP-1s are coming this year. The CEO in charge doesn't know what to expect

Peer Review

Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai

ImmunityBio's cell therapy posts encouraging early results in rare form of lymphoma

European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA

Europe Relies Too Much on China for Drugs, Fresenius CEO Warns

US drugmakers threaten to withhold products from Europe over prices

Treatment of a teenager with an ultra-rare condition is a medical milestone

The Economist

This year’s third major biotech buyout goes to GSK, which struck a deal to acquire RAPT Therapeutics for $2.2 billion. Check out Kyle LaHucik’s story here on what this means for the UK pharma giant and RAPT's turnaround after a bumpy 2024.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com